|4Feb 6, 7:58 AM ET

Carson Lisa Cabott 4

4 · Phio Pharmaceuticals Corp. · Filed Feb 6, 2026

Research Summary

AI-generated summary of this filing

Updated

Phio Pharmaceuticals (PHIO) CFO Carson Lisa Cabott Receives 47,000 RSUs

What Happened

  • Carson Lisa Cabott (CFO) received a grant of 47,000 restricted stock units (RSUs) on 2026-02-05. The reported acquisition price was $0.00 (typical for RSU awards); total reported value at grant was $0. These RSUs represent a compensation award, not an open-market purchase.

Key Details

  • Transaction date: 2026-02-05; Form filed: 2026-02-06 (timely filing).
  • Transaction type/code: Award/Grant (A); 47,000 shares acquired at $0.00.
  • Vesting: Footnote F1 — these RSUs will vest on the first annual anniversary of the grant (approximately 2027-02-05).
  • Holdings note: Footnote F2 indicates the filing’s reported holdings include shares underlying unvested RSUs.
  • No immediate sale or cashless exercise reported; this is a compensation grant rather than a market trade.

Context

  • RSU grants are common executive compensation and become actual shares only upon vesting; they do not by themselves signal a purchase intent. Retail investors should view this as part of compensation structure rather than an outright insider buy or sell.

Insider Transaction Report

Form 4
Period: 2026-02-05
Carson Lisa Cabott
Chief Financial Officer
Transactions
  • Award

    Common Stock, $.0001 par value

    [F1][F2]
    2026-02-05+47,00094,000 total
Footnotes (2)
  • [F1]Represents shares underlying a restricted stock unit, which shares will vest on the first annual anniversary of the grant.
  • [F2]Includes shares of common stock underlying unvested restricted stock units.
Signature
/s/ Lisa C. Carson|2026-02-06

Documents

1 file
  • 4
    ownership.xmlPrimary